行情

CANF

CANF

CAN FITE BIOPHAR
AMEX

实时行情|Nasdaq Last Sale

1.270
-0.010
-0.78%
已收盘, 16:00 04/02 EDT
开盘
1.300
昨收
1.280
最高
1.330
最低
1.265
成交量
9.77万
成交额
--
52周最高
10.50
52周最低
1.080
市值
1,114.13万
市盈率(TTM)
-0.3793
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CANF价格均价为7.00,最高价位9.00,最低价为5.00。

EPS

CANF 新闻

更多
  • Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020
  • Business Wire · 3天前
  • The Week In Cannabis: Marijuana Stocks Outperform S&P Again As Weed Is Deemed 'Essential' In COVID-19 Times
  • Benzinga · 4天前
  • Can-Fite Biopharma EPS beats by $4.17, beats on revenue
  • seekingalpha · 6天前
  • Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update
  • Business Wire · 6天前

所属板块

生物技术和医学研究
+2.93%
制药与医学研究
+2.57%

热门股票

代码
价格
涨跌幅

CANF 简况

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
展开

微牛提供Can Fite Biopharma Ltd(AMEX-CANF)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CANF股票新闻,以帮助您做出投资决策。